Bionime Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionime.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Medical Equipment winstgroei | 23.0% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2
Jul 22Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year
Jul 01These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong
Apr 29Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?
Mar 23Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?
Mar 05Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?
Feb 15Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet
Feb 01How Has Bionime (TPE:4737) Allocated Its Capital?
Jan 19A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE
Jan 06A Look At The Fair Value Of Bionime Corporation (TPE:4737)
Dec 22Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend
Dec 09Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment
Nov 24In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Bionime onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2024 | 1,858 | -40 | -308 | 101 | N/A |
3/31/2024 | 1,809 | 7 | -305 | 95 | N/A |
12/31/2023 | 1,756 | 6 | -238 | 203 | N/A |
9/30/2023 | 1,863 | 22 | -163 | 297 | N/A |
6/30/2023 | 2,002 | 43 | -109 | 284 | N/A |
3/31/2023 | 2,150 | 72 | 26 | 393 | N/A |
12/31/2022 | 2,211 | 91 | -171 | 142 | N/A |
9/30/2022 | 2,091 | 95 | -189 | 91 | N/A |
6/30/2022 | 2,023 | 115 | -139 | 129 | N/A |
3/31/2022 | 1,862 | 89 | -208 | 84 | N/A |
12/31/2021 | 1,850 | 87 | -15 | 270 | N/A |
9/30/2021 | 1,879 | 101 | 2 | 254 | N/A |
6/30/2021 | 1,832 | 111 | -58 | 205 | N/A |
3/31/2021 | 1,779 | 83 | -62 | 204 | N/A |
12/31/2020 | 1,669 | 62 | -79 | 218 | N/A |
9/30/2020 | 1,913 | 73 | -20 | 270 | N/A |
6/30/2020 | 1,951 | 38 | -4 | 247 | N/A |
3/31/2020 | 2,162 | 91 | 248 | 456 | N/A |
12/31/2019 | 2,173 | 106 | 267 | 406 | N/A |
9/30/2019 | 2,043 | 112 | 117 | 243 | N/A |
6/30/2019 | 2,113 | 132 | 55 | 208 | N/A |
3/31/2019 | 1,986 | 121 | -98 | 64 | N/A |
12/31/2018 | 2,007 | 128 | -47 | 122 | N/A |
9/30/2018 | 1,962 | 114 | 2 | 164 | N/A |
6/30/2018 | 1,842 | 135 | 40 | 166 | N/A |
3/31/2018 | 1,821 | 137 | N/A | 99 | N/A |
12/31/2017 | 1,820 | 150 | N/A | 30 | N/A |
9/30/2017 | 1,771 | 174 | N/A | 134 | N/A |
6/30/2017 | 1,780 | 181 | N/A | 275 | N/A |
3/31/2017 | 1,791 | 192 | N/A | 420 | N/A |
12/31/2016 | 1,740 | 179 | N/A | 458 | N/A |
9/30/2016 | 1,654 | 143 | N/A | 441 | N/A |
6/30/2016 | 1,637 | 119 | N/A | 373 | N/A |
3/31/2016 | 1,571 | 91 | N/A | 228 | N/A |
12/31/2015 | 1,610 | 99 | N/A | 200 | N/A |
9/30/2015 | 1,634 | 101 | N/A | 271 | N/A |
6/30/2015 | 1,591 | 82 | N/A | 305 | N/A |
3/31/2015 | 1,571 | 72 | N/A | 354 | N/A |
12/31/2014 | 1,525 | 54 | N/A | 360 | N/A |
9/30/2014 | 1,446 | 22 | N/A | 272 | N/A |
6/30/2014 | 1,459 | 43 | N/A | 148 | N/A |
3/31/2014 | 1,536 | 72 | N/A | 165 | N/A |
12/31/2013 | 1,561 | 90 | N/A | 129 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if 4737's forecast earnings growth is above the savings rate (1%).
Winst versus markt: Insufficient data to determine if 4737's earnings are forecast to grow faster than the TW market
Hoge groeiwinsten: Insufficient data to determine if 4737's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if 4737's revenue is forecast to grow faster than the TW market.
Hoge groei-inkomsten: Insufficient data to determine if 4737's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 4737's Return on Equity is forecast to be high in 3 years time